Literature DB >> 8856512

Contrasting migratory response of astrocytoma cells to tenascin mediated by different integrins.

A Giese1, M A Loo, S A Norman, S Treasurywala, M E Berens.   

Abstract

Tenascin, an extracellular matrix protein, is expressed in human gliomas in vitro and in vivo. The distribution of tenascin at the invasive edge of these tumors, even surrounding solitary invading cells, suggests a role for this protein as a regulator of glioma cell migration. We tested whether purified tenascin, passively deposited on surfaces, influenced the adhesion or migration of a human gliomaderived cell line, SF-767. Adhesion of glioma cells to tenascin increased in a dose-dependent fashion up to a coating concentration of 10 micrograms/ml. Higher coating concentrations resulted in progressively fewer cells attaching. Cell adhesion could be blocked to basal levels using anti-beta 1 integrin antibodies. In contrast, when anti-alpha v antibodies were added to the medium of cells on tenascin, cell adhesion was enhanced slightly. Using a microliter scale migration assay, we found that cell motility on tenascin was dose dependently stimulated at coating concentrations of 1 and 3 micrograms/ml, but migration was inhibited below levels of non-specific motility when tested at coating concentrations of 30 and 100 micrograms/ml. Migration on permissive concentrations of tenascin could be reversibly inhibited with anti-beta 1, while treatment with anti-alpha v antibodies increased migration rates. We conclude that SF-767 glioma cells express two separate integrin receptors that mediate contrasting adhesive and migratory responses to tenascin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856512     DOI: 10.1242/jcs.109.8.2161

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  15 in total

Review 1.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

2.  Hyaluronate receptors mediating glioma cell migration and proliferation.

Authors:  Y Akiyama; S Jung; B Salhia; S Lee; S Hubbard; M Taylor; T Mainprize; K Akaishi; W van Furth; J T Rutka
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

Review 3.  Role of tenascins in the ECM of gliomas.

Authors:  Nicole Brösicke; Andreas Faissner
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 4.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

5.  Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation.

Authors:  Senija Behrem; Kamelija Zarković; Neven Eskinja; Nives Jonjić
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

Review 6.  Toward 3D biomimetic models to understand the behavior of glioblastoma multiforme cells.

Authors:  Shreyas S Rao; John J Lannutti; Mariano S Viapiano; Atom Sarkar; Jessica O Winter
Journal:  Tissue Eng Part B Rev       Date:  2013-10-30       Impact factor: 6.389

Review 7.  Anti-angiogenic gene therapy in the treatment of malignant gliomas.

Authors:  NaTosha N Gatson; E Antonio Chiocca; Balveen Kaur
Journal:  Neurosci Lett       Date:  2012-08-10       Impact factor: 3.046

8.  Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway.

Authors:  Igor Paron; Sonja Berchtold; Julia Vörös; Madhavi Shamarla; Mert Erkan; Heinz Höfler; Irene Esposito
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

9.  Valproate, thalidomide and ethyl alcohol alter the migration of HTR-8/SVneo cells.

Authors:  Ujjwal K Rout
Journal:  Reprod Biol Endocrinol       Date:  2006-08-21       Impact factor: 5.211

10.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.